Join the Drug Discovery Innovators & Investors Digital Forum on 30 September 2026 for a virtual programme exploring the challenges, opportunities and emerging trends shaping early-stage drug discovery.
Bridging Academia and Industry for Breakthrough Innovation
Join top VCs, academic innovators and biopharma leaders at the 2nd Annual BioCentury Grand Rounds - Europe in Amsterdam, Sept. 23-25, 2026.
Examine the latest advances in disease biology, therapeutic modalities and enabling technologies with the experts shaping the future of medicine
Explore how to make R&D investible with experienced company-builders and early-stage investors
Early Bird Registration Closes September 30
*One Nucleus members can access a discount on the registration. Please email [email protected] for the code.
Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases
Two UK biotechs developing novel approaches to treating diseases such as psoriasis and Parkinson’s have secured investment and strategic support from Medicines Discovery Catapult (MDC) to accelerate their progress.
Flip Therapeutics and Nascent Therapeutics will each receive £500,000 in funding made available by Innovate UK as part of a scheme that enabled Catapults to invest in high-potential companies.
Join industry leaders, R&D experts, technology suppliers, and investors at the Drug Discovery Innovators & Investors London, UK Conference on 4 November 2026.
The day will explore how technology is reshaping the speed and effectiveness of clinical trials, where early-stage capital is flowing and how companies can access it, and what it takes to build and sustain a resilient, investment-ready drug development business in today’s market.
An exclusive in-person biotech development event hosted by Thermo Fisher Scientific in collaboration with One Nucleus in London, UK.
|
Join Thermo Fisher Scientific's local team for an exclusive in-person event designed to help biotech companies navigate critical development, manufacturing, and supply considerations on the path to the clinic. |
At Cancer Research UK, we exist to beat cancer.
At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success.
At Mestag we truly believe in our values and live by them every day. We’re ambitious about our science and its potential to deliver meaningful therapeutics to the patients that need them most. We believe in a culture of diversity, equality and investing in people to ensure our talented and passionate team members can fulfil their full potential.
Working at the intersection of science, innovation and investment, you'll spot promising technologies long before they reach the market and help shape them into investable businesses. One day you might be exploring a new area of research with a leading academic. The next, you'll be building an investment case, supporting a founder through fundraising, or helping secure backing from a syndicate of investors.